Price Action To Observe: Is Flex Pharma Inc’s Fuel Running Low? The Stock Reaches 1 Year Low Today

Price Action To Observe: Is Flex Pharma Inc's Fuel Running Low? The Stock Reaches 1 Year Low Today

The stock of Flex Pharma Inc (NASDAQ:FLKS) hit a new 52-week low and has $4.16 target or 14.00% below today’s $4.84 share price. The 8 months bearish chart indicates high risk for the $80.76 million company. The 1-year low was reported on Oct, 31 by If the $4.16 price target is reached, the company will be worth $11.31 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 39,054 shares traded hands. Flex Pharma Inc (NASDAQ:FLKS) has declined 57.84% since March 29, 2016 and is downtrending. It has underperformed by 61.31% the S&P500.

Analysts await Flex Pharma Inc (NASDAQ:FLKS) to report earnings on November, 2. They expect $-0.80 earnings per share, down 50.94% or $0.27 from last year’s $-0.53 per share. After $-0.71 actual earnings per share reported by Flex Pharma Inc for the previous quarter, Wall Street now forecasts 12.68% negative EPS growth.

Flex Pharma Inc (NASDAQ:FLKS) Ratings Coverage

Out of 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Flex Pharma has been the topic of 3 analyst reports since August 21, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald downgraded the stock to “Hold” rating in Friday, October 14 report. The firm has “Hold” rating given on Wednesday, September 2 by Zacks. On Friday, August 21 the stock rating was downgraded by Zacks to “Hold”.

According to Zacks Investment Research, “Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.”

More notable recent Flex Pharma Inc (NASDAQ:FLKS) news were published by: which released: “/quotes/zigman/3870025/realtime” on January 28, 2015, also with their article: “News Flex Pharma Inc.FLKS” published on January 24, 2015, published: “Boston’s Flex Pharma raises $86.4 million in IPO” on January 29, 2015. More interesting news about Flex Pharma Inc (NASDAQ:FLKS) were released by: and their article: “Flex Pharma Announces FLX-787 as Clinical Drug Candidate” published on November 10, 2015 as well as‘s news article titled: “Flex Pharma Announces Scientific Advisory Board Appointment and Management Change” with publication date: August 26, 2016.

FLKS Company Profile

Flex Pharma, Inc., incorporated on February 26, 2014, is a biotechnology firm that is developing treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Firm operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s product candidates are based on the mechanism of action described as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, is translated into a neuronal sensory signal that produces a beneficial effect. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing products using TRP activators.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment